The roles of PARK gene family in myopathy
Received date: 2022-04-11
Revised date: 2022-05-13
Online published: 2022-06-06
Supported by
Supported by the National Key R&D Program of China(2020YFA0803800);the National Natural Science Foundation of China No(31971097);Shanghai Academic/technology Research Leader of the Shanghai Science and Technology Innovation Program No(21XD1403200);the Construction Project of High-Level Local Universities in Shanghai and Multidisciplinary Cross-innovation Team of Metabolic Diseases in Chinese Medicine No(ZYYCXTD-D-202001)
The causative gene family of Parkinson's disease, PARK, plays important roles in the regulation of skeletal myopathy and is also involved in multiple biological processes, such as the modification of motor neurons, the transmission of nerve signals at the nerve-muscle junction, the regulation of skeletal muscle energy metabolism and mitochondrial quality, and the expression of myogenesis factors. PARK gene family regulates skeletal muscle mass, functions through a multi-level regulatory system, and plays a key role in the occurrence and development of skeletal myopathy. In this review, we summarize the structural characteristics, functions, and research of the PARK gene family in skeletal myopathy, providing a theoretical foundation and future research direction for in-depth study of the molecular mechanism for skeletal myopathy and giving references to further study on the role of PARK family in the development, the pathology, clinical diagnosis, and treatment of skeletal myopathy.
Shuang Zhang, Shanshan Guo, Ruwen Wang, Renyan Ma, Xianmin Wu, Peijie Chen, Ru Wang . The roles of PARK gene family in myopathy[J]. Hereditas(Beijing), 2022 , 44(7) : 545 -555 . DOI: 10.16288/j.yczz.22-105
| [1] | Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int, 2015, 96(3):183-195. |
| [2] | Zheng T, Gan ML, Shen LY, Niu LL, Guo ZY, Wang JY, Zhang SH, Zhu L,. circRNA on animal skeletal muscle development regulation. Hereditas(Beijing), 2020, 42(12):1178-1191. |
| [2] | 郑婷, 甘麦邻, 沈林園, 牛丽莉, 郭宗义, 王金勇, 张顺华, 朱砺. circRNA及其调控动物骨骼肌发育研究进展. 遗传, 2020, 42(12):1178-1191. |
| [3] | 姜明, 段春礼, 杨慧. PARK 基因家族与帕金森病研究进展. 生理科学进展, 2015, 46(2):133-136. |
| [4] | 巴茂文, 刘振国. 帕金森病遗传学研究进展. 中华老年医学杂志, 2003, 22(11):711-712. |
| [5] | 陈新新, 黄建平. 帕金森基因位点研究进展. 浙江中西医结合杂志, 2016, 26(8):776-780. |
| [6] | Liu TM, Xu Y, Yi CX, Tong QC, Cai DS. The hypothalamus for whole-body physiology: from metabolism to aging. Protein Cell, 2022, 13(6):394-421. |
| [7] | 黎罗明. 帕金森病遗传基因的研究进展. 海南医学院学报, 2012, 18(9):1339-1342. |
| [8] | 陈玉民, 崔桂云, 沈霞. 帕金森病的遗传学研究进展. 中国实用神经疾病杂志, 2012, 15(6):91-94. |
| [9] | Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int, 2007, 51(2-4):105-111. |
| [10] | Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev, 2004, 46(1):44-70. |
| [11] | Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen FS, Gu YJ, Hasegawa H, Salehi-Rad S, Wang LD, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A, . Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem, 2005, 280(40):34025-34032. |
| [12] | Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA, 2004, 101(24):9103-9108. |
| [13] | Crosiers D, Theuns J, Cras P, Van Broeckhoven C. Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat, 2011, 42(2):131-141. |
| [14] | Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 2004, 44(4):601-607. |
| [15] | Tong YR, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA, 2010, 107(21):9879-9784. |
| [16] | Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet, 2009, 18(R1):R48-R59. |
| [17] | Xiromerisiou G, Dardiotis E, Tsimourtou V, Kountra PM, Paterakis KN, Kapsalaki EZ, Fountas KN, Hadjigeorgiou GM. Genetic basis of Parkinson disease. Neurosurg Focus, 2010, 28(1):E7. |
| [18] | Pang GF, Qin JQ, Lv ZP, Yang Z, Hu CY. Research progress of genes related to Parkinson’s disease. Chin J Geriatr Care, 2015, 13(4):17-19. |
| [18] | 庞国防, 秦娇琴, 吕泽平, 杨泽, 胡才友. 帕金森病相关基因研究进展. 中国老年保健医学, 2015, 13(4):17-19. |
| [19] | Yang H, Zhou HY, Li B, Chen SD. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation. Neuroreport, 2005, 16(10):1117-1121. |
| [20] | Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol, 2019, 15(5):257-272. |
| [21] | Xiao H, Liang JQ, Liu SQ, Zhang QY, Xie FM, Kong XY, Guo SS, Wang RW, Fu R, Ye ZQ, Li Y, Zhang S, Zhang L, Kaudimba KK, Wang R, Kong XX, Zhao B, Zheng XQ, Liu TM. Proteomics and organoid culture reveal the underlying pathogenesis of Hashimoto's thyroiditis. Front Immunol, 2021, 12:784975. |
| [22] | Vencovský J, Alexanderson H, Lundberg IE. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am, 2019, 45(4):569-581. |
| [23] | Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A. Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol, 2000, 59(7):592-598. |
| [24] | de Camargo LV, de Carvalho MS, Shinjo SK, de Oliveira ASB, Zanoteli E. Clinical, histological, and immunohistochemical findings in Inclusion body myositis. Biomed Res Int, 2018, 2018:5069042. |
| [25] | Paciello O, Wójcik S, Engel WK, McFerrin J, Askanas V. Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. Acta Myol, 2006, 25(1):13-22. |
| [26] | Rosen KM, Veereshwarayya V, Moussa CEH, Fu QH, Goldberg MS, Schlossmacher MG, Shen J, Querfurth HW. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem, 2006, 281(18):12809-12816. |
| [27] | Terracciano C, Nogalska A, Engel WK, Wojcik S, Askanas V. In inclusion-body myositis muscle fibers Parkinson- associated DJ-1 is increased and oxidized. Free Radic Biol Med, 2008, 45(6):773-779. |
| [28] | Narayanappa G, Nandeesh BN. Infective myositis. Brain Pathol, 2021, 31(3):e12950. |
| [29] | Leduc-Gaudet JP, Mayaki D, Reynaud O, Broering FE, Chaffer TJ, Hussain SNA, Gouspillou G. Parkin overexpression attenuates sepsis-induced muscle wasting. Cells, 2020, 9(6):1454. |
| [30] | Furuya N, Ikeda SI, Sato S, Soma S, Ezaki J, Oliva Trejo JA, Takeda-Ezaki M, Fujimura T, Arikawa-Hirasawa E, Tada N, Komatsu M, Tanaka K, Kominami E, Hattori N, Ueno T. PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation. Autophagy, 2014, 10(4):631-641. |
| [31] | Kong XX, Yao T, Zhou P, Kazak L, Tenen D, Lyubetskaya A, Dawes BA, Tsai L, Kahn BB, Spiegelman BM, Liu TM, Rosen ED. Brown adipose tissue controls skeletal muscle function via the secretion of myostatin. Cell Metab, 2018, 28(4): 631-643.e3. |
| [32] | Peker N, Donipadi V, Sharma M, McFarlane C, Kambadur R. Loss of Parkin impairs mitochondrial function and leads to muscle atrophy. Am J Physiol Cell Physiol, 2018, 315(2):C164-C185. |
| [33] | Kim J, Won KJ, Jung SH, Lee KP, Shim SB, Kim MY, Kim JH, Lee JU, Kim B. DJ-1 protects against undernutrition-induced atrophy through inhibition of the MAPK-ubiquitin ligase pathway in myoblasts. Life Sci, 2015, 143:50-57. |
| [34] | Zhu XP, Yao T, Wang R, Guo SS, Wang X, Zhou ZQ, Zhang Y, Zhuo XZ, Wang RT, Li JZ, Liu TM, Kong XX. IRF4 in skeletal muscle regulates exercise capacity via PTG/Glycogen pathway. Adv Sci (Weinh), 2020, 7(19):2001502. |
| [35] | Yoda E, Hachisu K, Taketomi Y, Yoshida K, Nakamura M, Ikeda K, Taguchi R, Nakatani Y, Kuwata H, Murakami M, Kudo I, Hara S. Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca2+-independent phospholipase A2γ-deficient mice. J Lipid Res, 2010, 51(10):3003-3015. |
| [36] | Yamazaki K, Wakasugi N, Tomita T, Kikuchi T, Mukoyama M, Ando K. Gracile axonal dystrophy (GAD), a new neurological mutant in the mouse. Proc Soc Exp Biol Med, 1988, 187(2):209-215. |
| [37] | Gao HB, Freeling J, Wu PL, Liang AP, Wang XJ, Li YF. UCHL1 regulates muscle fibers and mTORC1 activity in skeletal muscle. Life Sci, 2019, 233:116699. |
| [38] | Gao HB, Hartnett S, Li YF. Ubiquitin C-Terminal Hydrolase L1 regulates myoblast proliferation and differentiation. Biochem Biophys Res Commun, 2017, 492(1):96-102. |
| [39] | Luan X, Tian XY, Zhang HX, Huang R, Li N, Chen PJ, Wang R. Exercise as a prescription for patients with various diseases. J Sport Health Sci, 2019, 8(5):422-441. |
| [40] | Leduc-Gaudet JP, Reynaud O, Hussain SN, Gouspillou G. Parkin overexpression protects from ageing-related loss of muscle mass and strength. J Physiol, 2019, 597(7):1975-1991. |
| [41] | Si HB, Ma P, Liang QY, Yin YJ, Wang P, Zhang Q, Wang SF, Deng HS. Overexpression of pink1 or parkin in indirect flight muscles promotes mitochondrial proteostasis and extends lifespan inDrosophila melanogaster. PLoS One, 2019, 14(11):e0225214. |
| [42] | Chen CCW, Erlich AT, Crilly MJ, Hood DA. Parkin is required for exercise-induced mitophagy in muscle: impact of aging. Am J Physiol Endocrinol Metab, 2018, 315(3):E404-E415. |
| [43] | Chen Y, Dorn GW. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science, 2013, 340(6131):471-475. |
| [44] | Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AHV, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet, 2010, 19(24):4861-4870. |
| [45] | Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol, 2010, 12(2):119-131. |
| [46] | Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 1988, 8(8):2804-2815. |
| [47] | Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 2000, 25(1):239-252. |
| [48] | Yavich L, Tanila H, Vepsäläinen S, Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci, 2004, 24(49):11165-11170. |
| [49] | Yavich L, Jäkälä P, Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha- synuclein knockout and A30P transgenic mice. J Neurochem, 2006, 99(3):724-732. |
| [50] | Pelkonen A, Yavich L. Neuromuscular pathology in mice lacking alpha-synuclein. Neurosci Lett, 2011, 487(3):350-353. |
| [51] | Vasu VT, Ott S, Hobson B, Rashidi V, Oommen S, Cross CE, Gohil K. Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of alpha-tocopherol deficient mice. Free Radic Res, 2009, 43(2):106-116. |
| [52] | Pietrzak A, Badura-Stronka M, Kangas-Kontio T, Felczak P, Kozubski W, Latos-Bielenska A, Wierzba-Bobrowicz T, Florczak-Wyspianska J. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome. Folia Neuropathol, 2019, 57(3):285-294. |
| [53] | Kline RA, Kaifer KA, Osman EY, Carella F, Tiberi A, Ross J, Pennetta G, Lorson CL, Murray LM. Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. PLoS Genet, 2017, 13(3):e1006680. |
| [54] | Gouspillou G, Godin R, Piquereau J, Picard M, Mofarrahi M, Mathew J, Purves-Smith FM, Sgarioto N, Hepple RT, Burelle Y, Hussain SNA. Protective role of Parkin in skeletal muscle contractile and mitochondrial function. J Physiol, 2018, 596(13):2565-2579. |
| [55] | Yang YF, Ouyang YS, Yang LC, Beal MF, McQuibban A, Vogel H, Lu BW. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA, 2008, 105(19):7070-7075. |
| [56] | Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell, 2014, 159(6):1253-1262. |
| [57] | Gao HB, Antony R, Srinivasan R, Wu PL, Wang XJ, Li YF. UCHL1 regulates oxidative activity in skeletal muscle. PLoS One, 2020, 15(11):e0241716. |
| [58] | Kuroda Y, Mitsui T, Kunishige M, Matsumoto T. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun, 2006, 348(3):787-793. |
| [59] | Shtifman A, Zhong N, Lopez JR, Shen J, Xu J. Altered Ca2+ homeostasis in the skeletal muscle of DJ-1 null mice. Neurobiol Aging, 2011, 32(1):125-132. |
| [60] | Shi SY, Lu SY, Sivasubramaniyam T, Revelo XS, Cai EP, Luk CT, Schroer SA, Patel P, Kim RH, Bombardier E, Quadrilatero J, Tupling AR, Mak TW, Winer DA, Woo M. DJ-1 links muscle ROS production with metabolic reprogramming and systemic energy homeostasis in mice. Nat Commun, 2015, 6:7415. |
| [61] | Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA, 2003, 100(7):4078-4083. |
| [62] | Hanagasi HA, Serdaroglu P, Ozansoy M, Basak N, Tasli H, Emre M. Mitochondrial pathology in muscle of a patient with a novel parkin mutation. Int J Neurosci, 2009, 119(10):1572-1583. |
| [63] | Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature, 2006, 441(7097):1157-1161. |
| [64] | Oláhová M, Thompson K, Hardy SA, Barbosa IA, Besse A, Anagnostou ME, White K, Davey T, Simpson MA, Champion M, Enns G, Schelley S, Lightowlers RN, Chrzanowska-Lightowlers ZMA, McFarland R, Deshpande C, Bonnen PE, Taylor RW. Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. J Inherit Metab Dis, 2017, 40(1):121-130. |
| [65] | Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol, 2019, 15(7):373-386. |
| [66] | Jones D. Duchenne muscular dystrophy awaits gene therapy. Nat Biotechnol, 2019, 37(4):335-337. |
| [67] | Boittin FX, Petermann O, Hirn C, Mittaud P, Dorchies OM, Roulet E, Ruegg UT. Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers. J Cell Sci, 2006, 119(Pt 18):3733-3742. |
| [68] | Ismail HM, Dorchies OM, Perozzo R, Strosova MK, Scapozza L, Ruegg UT. Inhibition of iPLA2 β and of stretch-activated channels by doxorubicin alters dystrophic muscle function. Br J Pharmacol, 2013, 169(7):1537-1550. |
| [69] | Baechler BL, Bloemberg D, Quadrilatero J. Mitophagy regulates mitochondrial network signaling, oxidative stress, and apoptosis during myoblast differentiation. Autophagy, 2019, 15(9):1606-1619. |
| [70] | Esteca MV, Severino MB, Silvestre JG, Dos Santos GP, Tamborlin L, Luchessi AD, Moriscot AS, Gustafsson ÅB, Baptista IL. Loss of parkin results in altered muscle stem cell differentiation during regeneration. Int J Mol Sci, 2020, 21(21):8007. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
